electroCore Third Quarter 2026 Earnings Call - ELECTROCORE INC

Explicit Guidance:

• Full-Year 2026 Revenue: Revised upward to $39–42 million from prior guidance of >30% YoY growth. This reflects a shift in timing, with acceleration expected in 2027 rather than the second half of 2026 due to sales force changes taking longer to fully materialize.
• Full-Year 2027 Revenue: Preliminary guidance for 30–40% YoY growth. This range is subject to refinement and updates in future quarters.
• Profitability Timeline: Target to achieve the first fiscal quarter of positive adjusted EBITDA by the end of 2027, assuming the execution of current strategic initiatives and the realization of the 2027 growth trajectory.
• Capital & Financing: Management currently believes the path to positive adjusted EBITDA can be achieved without entering into new dilutive equity capital financing transactions, supported by existing cash on hand and financing resources.
• Refinancing Options: Actively evaluating options to refinance the existing term loan, including extending principal repayment timing, to support cash runway and balance sheet strength. No agreements have been finalized.
• Operating Metrics (Future Targets): Goal to increase the national refill rate from 42% (YTD Sept 2026) to >70%. Expected to drive improvements beginning in Q4 2026 with additional gains in early 2027.
• VA Sales Channel: Intending to route all future VA channel sales through Lovell Government Services (effective August 2026), expected to reduce transaction fees by ~3%.

Business-Segment Outlook:

• CIPN (Chemotherapy-Induced Peripheral Neuropathy): Filed 510K pre-market notification with FDA for Quell wearable stimulation device on October 27, 2026. If cleared, this offers a new non-drug option with no current medical device or pharmaceutical competitors.
• CIPN Commercialization: Anticipates potential sales generation starting in the back half of 2027 if FDA clearance is received in the back half of Q1 2027. Potential revenue impact described as "gravy" or incremental upside to the core 2027 forecast.
• VA Market Penetration: Goal to have 14 new patients per month per account across both GammaCore and Quell products. Current focus on expanding coverage to facilities not yet prescribing Quell (approx. 70% of VA accounts currently non-prescribing).
• DTC (Direct-to-Consumer) / TrueVe: Revenue expected to grow YoY but at a slowed rate compared to 2025. Management is intentionally avoiding "empty calorie" growth to prioritize profitability and Return on Advertising Spend (ROAS).
• New Markets:
  • Department of Defense/TRICARE: Engaged with key stakeholders in Q3 2026; pilot areas for federal workers' compensation identified but discussions paused pending further validation.
  • Commercial Channels: Kaiser engagement ongoing for coverage outside California; QWel evaluation in California showing positive results.
  • First Responders & Federal Workers: Contracts initiated with First Responders Consultants; ongoing discussions with VA Women's Health.

Market and Competitive Outlook:

• CIPN Market Size: Addressable market estimated at $600M–$700M in the US (approx. 50% of chemo patients experiencing neurotoxicity) and $15M–$20M within the VA.
• Competitive Landscape: CIPN indication identified as a "blue ocean" opportunity due to the absence of other approved medical devices or pharmaceuticals specifically indicated for this condition.
• Sales Force Efficiency: New representatives (added since June) are producing ~$210,000/month (vs. $160,000 previously), trending toward $300,000/month. New patient starts reached 3.4 per account by the third month (vs. 0.3 previously), with account growth taking ~2 months vs. 6–7 months historically.
• VA Concentration: Revenue diversification improving; top 15 accounts dropped from 54% to 51% of revenue, and no single facility accounts for more than 10% of VA net sales. Top 30 accounts (top quarter of base) dropped from 73% to 71%.
• Product Performance: October 2026 marked the best month on record for Quell Fibromyalgia, surpassing 1,000 VA patients prescribed Quell in 2026 alone.

Macro / Industry Outlook:

• Regulatory Environment: FDA review of 510K for CIPN is ongoing; target for response is 90 review days, with potential feedback expected in the second half of Q1 2027. An open Form 483 from 2017 is not expected to delay the current submission.
• Pricing & Reimbursement: Shift to Lovell Government Services for VA sales expected to reduce transaction costs by 3%. Commercial reimbursement discussions (e.g., Kaiser) are ongoing.
• Economic Sensitivity: No explicit macro-economic commentary regarding rates or inflation, though management emphasizes the strategic importance of "financial discipline" and "operating leverage" in the current environment.

Strategic Initiatives:

• Sales Force Restructuring: Split Vice President of Sales role into East and West Area VPs with six Regional Sales Directors. Added two new regional directors in October (a third following), aiming for full staffing by October 2026.
• Territory Optimization: Moving to smaller territories with clearer accountability and "blueprint" replication from the high-performing Southeast and Northeast regions to the national level.
• Capacity & Supply: Inventory increased to $4 million (from $1.6 million at year-end 2025) to support forecasted growth in prescription business.
• Patient Compliance: Piloting new patient training initiatives to improve therapy compliance, aiming to drive refill rates to 70%.
• M&A/Partnerships: Active engagement with First Responders Consultants and VA Women's Health to expand channel coverage.
• OTC Product (Quell 2.0): Launch of over-the-counter Quell product delayed pending resolution of 2017 Form 483 issues and market validation for profitable execution.

Risks and Headwinds to Outlook:

• FDA Regulatory Risk: CIPN 510K clearance is uncertain; FDA could request additional data or delay review. Approval timeline remains the primary driver for CIPN revenue realization.
• Sales Force Ramp: Acceleration in revenue growth (30–40% in 2027) depends on the successful national rollout of the new sales model and the retention/performance of new reps.
• Reimbursement Risks: Expansion into commercial markets (outside VA) faces hurdles regarding coverage and reimbursement policies.
• Operational Execution: Success in reaching positive EBITDA by end-2027 relies on continued OPEX discipline, successful refactoring of sales territories, and achieving refill rate targets.
• DTC Competition: Increasing competition in branded search terms (up 60%) has raised Cost Per Click (up 42%), necessitating continued focus on profitability over top-line volume.

Management Tone on the Future:

• Confidence: High conviction in the 2027 trajectory, citing "early proof" that the new sales model is working. Management views the 2026 guidance revision as a "change in timing, not direction."
• Strategic Focus: Emphasis on "long-term durable revenue" and "profitable scale" over short-term top-line growth. Language shifts from "survival" to "inflection point."
• Hedging: Standard disclaimers regarding FDA unpredictability and the "no assurance" of refinancing outcomes. Acknowledgment that CIPN revenue in 2027 would be incremental upside rather than a baseline assumption.

Miscellaneous:

• Timeline Note: All statements and guidance are accurate as of November 4, 2026.
• Divestiture History: Quell Fibromyalgia products acquired from Neurometrics, Inc. in May 2025, now a core component of VA revenue.
• Financial Position: Cash, cash equivalents, and marketable securities at $7.5 million as of September 30, 2026.